Topic: Huntington disease
By examining the role played by star-shaped brain cells called astrocytes, UCLA scientists identified a potential strategy to fight Huntington's.
Two years after it walked away from a Voyager Therapeutics-partnered Parkinson’s gene therapy, Sanofi Genzyme is at it again.
Locana raised $55 million to expand its platform and pipeline for diseases caused by problems in RNA that stop the production of essential proteins.
Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.
The cash will fund midphase trials of an ex-Vertex drug in dementia and Huntington's disease.
Ribometrix raised $30 million to fund its platform that fits small molecules into the 3D folds and pockets of RNA structures to modulate their activity.
Laquinimod was once hailed as a blockbuster heir to Copaxone but suffered a string of late-phase failures that dragged down Teva.
Active Biotech and Teva delivered more bad news from their clinical development of laquinimod, this time from a phase 2 trial in Huntington’s disease.
Vaccinex filed a $46 million Nasdaq IPO to support its development of antibodies and conjugates targeting neurodegenerative diseases and cancer.
Celgene launched a $60 million collaboration with Skyhawk Therapeutics to develop small molecules targeting RNA mis-splicing in neurological diseases.